Hematologist
CION Cancer Clinics
Favourable, intermediate, adverse: what your leukaemia risk group means | CION Cancer Clinics
A leukaemia risk group sorts the disease by how it is likely to respond to standard treatment. Favourable, intermediate and adverse are decided mainly by gene and chromosome changes in the leukaemia cells. The label helps your haematologist choose what comes after the first treatment, including whether a transplant should be discussed. It does not predict what will happen to you. At CION Cancer Clinics, our haematologist reviews abnormal blood reports with you, orders only the tests that answer your question and explains each result plainly.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does a leukaemia risk group actually mean?
- What do favourable, intermediate and adverse each mean?
- How is your risk group worked out?
- Which words on the report go with the risk group?
- What do families often get wrong about risk groups?
- What can a risk group not tell you?
- Common questions about leukaemia risk groups
The short answer
What does a leukaemia risk group actually mean?
A risk group is a label that sorts leukaemia by how it is likely to behave with standard treatment. Favourable, intermediate and adverse are the three groups most reports use. The label comes mainly from the gene and chromosome changes inside the leukaemia cells, not from how unwell you feel today.
Why doctors sort leukaemia this way
Two people can both have acute myeloid leukaemia (AML) and need very different plans. The changes inside the cells help predict how well the leukaemia responds to chemotherapy and how likely it is to come back. The risk group turns that into one word the whole team can plan around.
What it mostly decides
For many people, the risk group shapes the plan after the first phase of treatment. It helps decide whether more chemotherapy is likely to be enough, or whether a stem cell transplant should be discussed while the leukaemia is under control. It can also point to a targeted medicine that suits a particular gene change.
Who this label does not fully apply to
The favourable, intermediate and adverse system is used most for AML. Acute lymphoblastic leukaemia (ALL), chronic leukaemias and myeloma use their own systems with different names. If your report uses other words, ask your haematologist which system it follows.
A risk group describes the leukaemia, not the person. Your age, fitness and other illnesses are weighed separately.The three labels
What do favourable, intermediate and adverse each mean?
These are broad groups. Each holds many different gene changes, and your own plan depends on which one you have.
Favourable
The leukaemia carries changes that usually respond well to standard chemotherapy. The chance of it coming back is lower than in the other groups. It still needs full, intensive treatment.
Often seen with
- Certain chromosome swaps, such as t(8;21)
- Some NPM1 gene changes
Intermediate
The changes found do not clearly point either way. This group is where the most discussion happens. Response to the first treatment and later tests often decide the next step.
A normal chromosome result with no key gene change often lands here.Adverse
The leukaemia carries changes linked with a weaker response or a higher chance of coming back. It does not mean treatment is pointless. It usually means the team plans further ahead, often including a transplant discussion early.
Often seen with
- TP53 gene changes
- Complex chromosome results
Not sure whether this applies to you?
Ask an oncologistHow the label is reached
How is your risk group worked out?
The marrow sample
A bone marrow test collects leukaemia cells. The same sample is used for the microscope report, flow cytometry and the genetic tests, so one procedure usually serves all of them.
Chromosome tests
Karyotype and FISH look for large changes, such as pieces of chromosome swapped or missing. These results often arrive before the gene panel does.
Gene tests
A PCR test or an NGS panel looks for small changes in single genes. Some of these move a patient from one group into another, which is why the label can change once they arrive.
Putting it together
Your haematologist applies a published system, often the European LeukemiaNet one for AML, and discusses the result with the wider team before settling the plan.
On your report
Which words on the report go with the risk group?
- Cytogenetics
- The study of chromosomes in the leukaemia cells. A karyotype is the picture of them.
- Molecular
- Tests for changes in single genes, such as FLT3, NPM1 or TP53.
- ELN classification
- The European LeukemiaNet system that many teams use to assign AML risk groups.
- Complex karyotype
- Several separate chromosome changes found together. It usually places AML in the adverse group.
- Remission
- No sign of leukaemia on the usual tests after treatment. It is a milestone, not the end of care.
- MRD
- Measurable residual disease: very small amounts of leukaemia found by sensitive tests after treatment.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Did you know
A risk group can be revised. If a gene result arrives late, or the leukaemia responds differently than expected, the team may move you into another group and change the plan to match.
Commonly believed
What do families often get wrong about risk groups?
"Adverse means there is nothing to be done."
Adverse describes how the leukaemia tends to behave with standard treatment. It is a reason to plan carefully and early, often with a transplant centre in the conversation. It is not a reason to stop treatment or to give up.
"Favourable means we can relax the treatment."
Favourable leukaemia still needs the full course. Cutting cycles short or delaying them because the label sounds reassuring can undo the advantage the label describes.
"The risk group is decided on the first day."
Chromosome and gene results can take longer than the first report. The label is often confirmed only once they arrive, and it can shift again after the response to treatment is measured.
"Someone else in the same group will have the same outcome."
A group holds many different people and many different gene changes. Age, fitness and response to treatment all matter too. Comparing yourself with another family's story rarely helps.
Being straight with you
What can a risk group not tell you?
A risk group cannot tell you what will happen to you. It describes how a large group of people with similar leukaemia tended to respond. Your own course depends on many things the label does not include.
It is not a timeline
Nothing in the words favourable, intermediate or adverse tells you how long treatment will take or how long anyone will live. Please do not read online survival figures against the label. They are often old, from other countries, and from people treated differently.
What to ask your haematologist
Ask which system was used and which result placed you in the group. Ask whether any tests are still pending that could change it. Ask whether a transplant is part of the plan, and if so, which centre the team would refer you to and when that conversation should start.
If you want another opinion
It is reasonable to ask for your reports to be reviewed again. At CION, Dr. Basudev Pokhrel and the haematology team read the marrow, chromosome and gene reports together and discuss the case at a tumour board before explaining the plan to you.
Questions we are asked
Common questions about leukaemia risk groups
Is intermediate risk good or bad?
Neither, on its own. It means the gene and chromosome changes found do not clearly point towards a better or weaker response. Much depends on how the leukaemia responds to the first phase of treatment and what later tests show. Your haematologist will explain which way your results lean.
Can my risk group change after treatment starts?
Yes. A gene result that arrives after treatment begins can move you into another group. How the leukaemia responds, and whether small amounts remain on sensitive tests, can also change the plan. This is normal and does not mean the first label was a mistake.
Does adverse risk mean I need a transplant?
Often a transplant is discussed, but it is not automatic. It depends on your age, fitness, other illnesses, response to treatment and whether a suitable donor can be found. CION does not perform transplants itself. The team will explain whether referral makes sense and help coordinate it.
Why did the doctor start treatment before knowing the risk group?
Acute leukaemia can become dangerous quickly, and the first phase of treatment is similar for many risk groups. Waiting for every gene result could mean waiting while the counts fall. The later results usually shape the plan after that first phase, or add a targeted medicine.
Does the risk group apply to chronic leukaemia too?
Not in the same way. Chronic lymphocytic leukaemia, chronic myeloid leukaemia and myeloma each use their own scoring systems with different names and different tests. If your report uses unfamiliar terms, ask your haematologist which system applies to your diagnosis and what it means for the plan.
My report does not mention a risk group. Is something missing?
Not necessarily. The risk group is usually written in the haematologist's summary, not the laboratory report. It may also be waiting for chromosome or gene results. Ask at your next visit whether all the tests needed to assign the group have been sent and reported.
Can I find my chances online using the risk group?
We would gently advise against it. Figures online are averages from other people, other years and other treatments. They cannot account for your fitness, your exact gene changes or how you respond. Your haematologist is the right person to talk through your own outlook.
Can family members be tested for the same changes?
Most gene changes used for risk grouping arise in the leukaemia cells only and are not passed on. A few can be inherited. If your team suspects one, they will suggest a separate test and may discuss testing relatives, especially if a family member is being considered as a donor.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Acute Myeloid Leukemia (AML)
- Cancer Research UK — Acute myeloid leukaemia (AML)
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Karyotype and FISH in Leukaemia: Why They Change TreatmentThe chromosome tests behind most risk groupsMyeloid NGS Panels: What Gets Tested and WhyThe gene results that can move you between groupsMinimal Residual Disease: The Number After TreatmentHow response to treatment refines the planGetting a Haematology Diagnosis: Marrow, Flow and MolecularThe whole diagnostic pathway in one place
Talk to us
Have a marrow or gene report you want explained?
Share it with us or call the helpline. The haematology team will go through what the result means and what to ask next. One helpline serves every CION centre.